{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:17:22Z","timestamp":1790007442287,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Propionic acidemia (PA) is a rare disease resulting in toxic accumulation of metabolites that cause metabolic decompensation events (MDEs). Natural history characterization of PA is limited partly due to its rarity and complexity. This study examined clinical events in participants with PA and their correlation with biomarkers to better understand the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants diagnosed with PA (early- versus late-onset) were evaluated every 6\u2009months from baseline to month 36. Outcome measures included annualized MDEs and changes in 3-hydroxypropionic acid (3-HP), 2-methylcitrate (2-MC), and propionylcarnitine (C3) concentrations. Blood samples were collected at each visit and during MDEs for plasma biomarker analyses. Relative risk (RR) was calculated based on MDE rates and biomarker levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most participants (n\/\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200949\/50, 98.0%) reported MDEs. Annualized MDE rates were highest in participants aged 0 to\u2009\u2264\u20091 and\u2009&gt;\u20091 to\u2009\u2264\u20092 versus\u2009&gt;\u200912 to \u2264 18\u2009years (2.6 and 2.4, respectively, vs 0.2) and for early-onset versus late-onset PA (1.2 vs 0.3). A 50% decrease in plasma biomarkers was associated with a statistically significant reduction in RR of MDEs for 3-HP (RR: 0.7, 95% CI: 0.6\u20130.9;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and a substantial reduction for C3 (RR: 0.6, 95% CI: 0.4\u20130.9;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017); no effect was observed for 2-MC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MDE rates were higher in the youngest participants (0 to \u2264 2\u2009years) versus participants aged\u2009&gt;\u200912\u2009years, and with early- versus late-onset PA. Lower concentrations of 3-HP and C3 were associated with a reduced MDE risk. These findings may guide biomarker or clinical endpoints in future treatment trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04251-3","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:47:00Z","timestamp":1773046020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterizing the frequency of clinical events and assessing biomarkers in propionic acidemia: a natural history study"],"prefix":"10.1186","volume":"21","author":[{"given":"Bernd C.","family":"Schwahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard T.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary J.","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Lawrence","family":"Merritt II","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Chabrol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"De las Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Vockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight D.","family":"Koeberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara K.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Grunewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Ficicioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husain","family":"Attarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6086-8389","authenticated-orcid":false,"given":"Sue","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Sikirica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"4251_CR1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/jimd.12370","volume":"44","author":"P Forny","year":"2021","unstructured":"Forny P, H\u00f6rster F, Ballhausen D, Chakrapani A, Chapman KA, Dionisi-Vici C, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J Inherit Metab Dis. 2021;44:566\u201392","journal-title":"J Inherit Metab Dis"},{"key":"4251_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13023-018-0987-z","volume":"14","author":"T Alm\u00e1si","year":"2019","unstructured":"Alm\u00e1si T, Guey LT, Lukacs C, Csetneki K, Vok\u00f3 Z, Zelei T. Systematic literature review and meta-analysis on the epidemiology of propionic acidemia. Orphanet J Rare Dis. 2019;14:40","journal-title":"Orphanet J Rare Dis"},{"key":"4251_CR3","first-page":"106","volume":"15","author":"KA Chapman","year":"2018","unstructured":"Chapman KA, Gramer G, Viall S, Summar ML. Incidence of maple syrup urine disease, propionic acidemia, and methylmalonic aciduria from newborn screening data. Mol Genet Metab Rep. 2018;15:106\u201309","journal-title":"Mol Genet Metab Rep"},{"key":"4251_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/jimd.12478","volume":"45","author":"N Longo","year":"2022","unstructured":"Longo N, Sass JO, Jurecka A, Vockley J. Biomarkers for drug development in propionic and methylmalonic acidemias. J Inherit Metab Dis. 2022;45:132\u201343","journal-title":"J Inherit Metab Dis"},{"key":"4251_CR5","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnert SC, M\u00fcllerleile S, Silva LD, Barth M, Walter M, Walter K, et al. Propionic acidemia: clinical course and outcome in 55 pediatric and adolescent patients. Orphanet J Rare Dis. 2013;8:6","DOI":"10.1186\/1750-1172-8-6"},{"key":"4251_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10545-017-0116-5","volume":"41","author":"J Heringer","year":"2018","unstructured":"Heringer J, Valayannopoulos V, Lund AM, Wijburg FA, Freisinger P, Bari\u0107 I, et al. Correction to: impact of age at onset and newborn screening on outcome in organic acidurias. J Inherit Metab Dis. 2018;41:741\u201342","journal-title":"J Inherit Metab Dis"},{"key":"4251_CR7","unstructured":"Galarreta Aima CI, Shchelochkov OA, Jerves Serrano T, Venditti CP. in: Adam, MP, Feldman, J, Mirzaa, GM, Pagon, RA, Wallace, SE, Amemiya, A, eds GeneReviews\u00ae Propionic acidemia. 2024"},{"key":"4251_CR8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/MOP.0000000000000422","volume":"28","author":"JL Fraser","year":"2016","unstructured":"Fraser JL, Venditti CP. Methylmalonic and propionic acidemias. Curr Opin Pediatr. 2016;28:682\u201393","journal-title":"Curr Opin Pediatr"},{"key":"4251_CR9","doi-asserted-by":"publisher","first-page":"107695","DOI":"10.1016\/j.ymgme.2023.107695","volume":"140","author":"H Barman","year":"2023","unstructured":"Barman H, Sikirica V, Carlson K, Silvert E, Carlson KB, Boyer S, et al. Retrospective study of propionic acidemia using natural language processing in mayo clinic electronic health record data. Mol Genet Metab. 2023;140:107695","journal-title":"Mol Genet Metab"},{"key":"4251_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/jimd.12128","volume":"42","author":"HA Haijes","year":"2019","unstructured":"Haijes HA, van HPM, Jans JJM, Verhoeven-Duif NM. Pathophysiology of propionic and methylmalonic acidemias. Part, 2: treatment strategies. J Inherit Metab Dis. 2019;42:745\u201361","journal-title":"J Inherit Metab Dis"},{"key":"4251_CR11","doi-asserted-by":"publisher","first-page":"107612","DOI":"10.1016\/j.ymgme.2023.107612","volume":"139","author":"J Vockley","year":"2023","unstructured":"Vockley J, Burton B, Jurecka A, Ganju J, Leiro B, Zori R, et al. Challenges and strategies for clinical trials in propionic and methylmalonic acidemias. Mol Genet Metab. 2023;139:107612","journal-title":"Mol Genet Metab"},{"key":"4251_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1471082X17748083","volume":"18","author":"A Bender","year":"2017","unstructured":"Bender A, Groll A, Scheipl F. A generalized additive model approach to time-to-event analysis. Stat Model. 2017;18:299\u2013321","journal-title":"Stat Model"},{"key":"4251_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ymgme.2011.09.022","volume":"105","author":"L Pena","year":"2012","unstructured":"Pena L, Franks J, Chapman KA, Gropman A, Mew NA, Chakrapani A, et al. Natural history of propionic acidemia. Mol Genet Metab. 2012;105:5\u20139","journal-title":"Mol Genet Metab"},{"key":"4251_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1750-1172-8-148","volume":"8","author":"M Nizon","year":"2013","unstructured":"Nizon M, Ottolenghi C, Valayannopoulos V, Arnoux J-B, Barbier V, Habarou F, et al. Long-term neurological outcome of a cohort of 80 patients with classical organic acidurias. Orphanet J Rare Dis. 2013;8:148","journal-title":"Orphanet J Rare Dis"},{"key":"4251_CR15","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/lt.25304","volume":"24","author":"K Critelli","year":"2018","unstructured":"Critelli K, McKiernan P, Vockley J, Mazariegos G, Squires RH, Soltys K, et al. Liver transplantation for propionic acidemia and Methylmalonic acidemia: perioperative management and clinical outcomes. Liver Transpl. 2018;24:1260\u201370","journal-title":"Liver Transpl"},{"key":"4251_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/PEC.0000000000001028","volume":"33","author":"SH Aldubayan","year":"2017","unstructured":"Aldubayan SH, Rodan LH, Berry GT, Levy HL. Acute illness protocol for organic acidemias. Pediatr Emerg Care. 2017;33:142\u201346","journal-title":"Pediatr Emerg Care"},{"key":"4251_CR17","doi-asserted-by":"crossref","unstructured":"Ahmad AH, Henley K, Asencio J, Gupta A, Totapally B. Hypoglycemia among young Children Presenting with metabolic acidosis. Cureus. 2024;16:e72232","DOI":"10.7759\/cureus.72232"},{"key":"4251_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0736-4679(03)00100-8","volume":"25","author":"LP Daly","year":"2003","unstructured":"Daly LP, Osterhoudt KC, Weinzimer SA. Presenting features of idiopathic ketotic hypoglycemia. J Emerg Med. 2003;25:39\u201343","journal-title":"J Emerg Med"},{"key":"4251_CR19","unstructured":"Insights NR. Barriers to rare disease diagnosis, care and treatment in the US: a 30-year comparative analysis. 2023"},{"key":"4251_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4097\/kjae.2013.65.3.257","volume":"65","author":"J Ryu","year":"2012","unstructured":"Ryu J, Shin YH, Ko JS, Gwak MS, Kim G-S. Intractable metabolic acidosis in a child with propionic acidemia undergoing liver transplantation -a case report-. Korean J Anesthesiol. 2012;65:257\u201361","journal-title":"Korean J Anesthesiol"},{"key":"4251_CR21","doi-asserted-by":"publisher","first-page":"807822","DOI":"10.3389\/fgene.2022.807822","volume":"13","author":"G Ji","year":"2022","unstructured":"Ji G, Liu Y, Song X, Li Z. Case report: novel Mutations in the PCCB gene causing late-onset propionic acidemia. Front Genet. 2022;13:807822","journal-title":"Front Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04251-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04251-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04251-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:37:23Z","timestamp":1781638643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04251-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4251"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04251-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Access to participant-level data presented in this article and supporting clinical documents with external researchers who provide methodologically sound scientific proposals will be available upon reasonable request for products or indications that have been approved by regulators in the relevant markets and subject to review. Such requests can be made to: Moderna Inc., 325 Binney St., Cambridge, MA 02142 USA or at data_sharing@modernatx.com. A materials transfer and\/or data access agreement with the sponsor will be required for accessing shared data. All other relevant data are presented in the paper. The protocol is available online at ClinicalTrials.gov: NCT03484767; registered on 2 April 2018.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This study abided by all applicable laws and regulations including but not limited to Good Clinical Practices (GCP), Good Pharmacoepidemiology Practices (GPP), Good Pharmacovigilance Practices (GVP), the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology, the ethical principles that have their origins in the Declaration of Helsinki, and applicable privacy laws. Consistent with local regulations and prior to enrollment of participants at a given site, the study protocol was submitted together with its associated documents (eg, ICF) to the responsible Institutional Review Board\/Independent Ethics Committee (IRB\/IEC) for its review. Participant enrollment did not start at any site before the site obtained written confirmation of a favorable opinion\/approval from the relevant central or local IRB\/IEC and an approved informed consent\/assent form. (IRB: 00104172).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BCS reports clinical trial sponsorship (paid to institution) and advisory board participation for Moderna, Inc. GTB: nothing to disclose HJV: reports research funding and advisory board participation for Moderna, Inc. HL: reports research funding from Moderna, Inc. JLM: nothing to disclose MS reports consulting fees from IECure, LogicBio, and Ultragenyx; honoraria from Immedica; and clinical trial sponsorship from Arcturus and Moderna, Inc BC: nothing to disclose. JDH: has been a consultant for Moderna, Inc. JV: Received consulting fees and research support from Moderna, Inc. CL: nothing to disclose. DK: DK has served as a consultant for Sangamo Therapeutics, Moderna, Genzyme Sanofi, Amicus, and Vertex; has received grant support from Viking Therapeutics, Genzyme Sanofi, Roivant Rare Diseases, and Amicus; and has held equity in Asklepios Biopharmaceutical (AskBio), which is developing gene therapy for Pompe disease. BKB: has received consulting fees and research support from Moderna, Inc. for service on a DSMB. SG: has conducted clinical trials and received consultancy fees and\/or honoraria from Ultragenyx, Origin, Zevra, Glycomine and Moderna, Inc. GAD: nothing to disclose. CF: Received grant support from Moderna, Inc.TM: has conducted clinical trials for LogicBio, Sanofi\/Genzyme, Mallinckrodt, and previously served as an employee of Novartis and of Biomarin Pharmaceutical, Inc. JL: employee of Moderna, Inc at the time of the study and holds stock in Moderna, Inc. HA: employee of Moderna, Inc at the time of the study and holds stock in Moderna, Inc. ML: employee of and holds stock in Moderna, Inc. SP: employee of and holds stock in Moderna, Inc. VS: employee of and holds stock in Moderna, Inc.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}